Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA® (Pembrolizumab) in Selected Advanced Solid Tumors
Go back to Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA® (Pembrolizumab) in Selected Advanced Solid Tumors| Goss & De Leeuw Mach Co (NASDAQ: GOSS) | Delayed: 11.95 +0.67 (5.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.28 | 52 Week High | $0.00 | |||
| Open | $11.48 | 52 Week Low | $0.00 | |||
| Day High | $12.08 | P/E | N/A | |||
| Day Low | $11.35 | EPS | $0.00 | |||
| Volume | 116,844 | |||||
